{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:07:55Z","timestamp":1790255275542,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201315","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:08:57Z","timestamp":1785701337000},"page":"201315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["An inducible signal 1 booster overcomes limited access to antigen for solid tumor cell therapy"],"prefix":"10.1016","volume":"34","author":[{"given":"Kelly C.","family":"Radecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3301-7517","authenticated-orcid":false,"given":"Diane","family":"Manry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Kirsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anagha","family":"Krishnagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaia","family":"Sima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julyun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Partin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breanna","family":"DiAndreth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201315_bib1","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2026.201315_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010976","article-title":"Onboard, tethered IL-12 boosts potency of the Tmod NOT gate and preserves selectivity","volume":"13","author":"Zhang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201315_bib3","article-title":"Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201315_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109030","article-title":"The Tmod cellular logic gate as a solution for tumor-selective immunotherapy","volume":"241","author":"DiAndreth","year":"2022","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.omton.2026.201315_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010702","article-title":"Tailoring CAR surface density and dynamics to improve CAR-T cell therapy","volume":"13","author":"Hinckley-Boned","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201315_bib6","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jcyt.2025.06.014","article-title":"Detailed analysis of the effects of a NOT gate on activation and growth of T cells","volume":"27","author":"Ando","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omton.2026.201315_bib7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4049\/immunohorizons.2100033","article-title":"Design of TCR Structural Variants That Retain or Invert the Normal Activation Signal","volume":"5","author":"Mock","year":"2021","journal-title":"ImmunoHorizons"},{"key":"10.1016\/j.omton.2026.201315_bib8","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1073\/pnas.95.18.10437","article-title":"Redesigning an FKBP\u2013ligand interface to generate chemical dimerizers with novel specificity","volume":"95","author":"Clackson","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201315_bib9","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.ymthe.2017.06.014","article-title":"Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88\/CD40","volume":"25","author":"Foster","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201315_bib10","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1172\/JCI44327","article-title":"A composite MyD88\/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy","volume":"121","author":"Narayanan","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201315_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-53220-6","article-title":"PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial","volume":"15","author":"Stein","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201315_bib12","doi-asserted-by":"crossref","first-page":"10168","DOI":"10.1021\/bi9909905","article-title":"High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization","volume":"38","author":"Pullen","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.omton.2026.201315_bib13","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1128\/jvi.71.3.1776-1783.1997","article-title":"Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line - PubMed","volume":"71","author":"Malik","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201315_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109913","article-title":"NOT gated T cells that selectively target EGFR and other widely expressed tumor antigens","volume":"27","author":"Oh","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.omton.2026.201315_bib15","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy - PubMed","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201315_bib16","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/00912700122010771","article-title":"Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers","volume":"41","author":"Iuliucci","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.omton.2026.201315_bib17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201315_bib18","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192203","article-title":"Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression","volume":"218","author":"Lanitis","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201315_bib19","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/s41375-019-0417-9","article-title":"Constitutively active MyD88\/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies","volume":"33","author":"Collinson-Pautz","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201315_bib20","first-page":"A367","article-title":"323 Preclinical development of AB-1015, an integrated circuit T cell therapy containing an ALPG\/MSLN logic gate and FAS\/PTPN2 shRNA-miR, for the treatment of ovarian cancer","volume":"11","author":"Yun","year":"2023","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.omton.2026.201315_bib21","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201315_bib22","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-Negative TGF-\u03b2 Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201315_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.molimm.2020.07.020","article-title":"Structure-function relationships of chimeric antigen receptors in acute T cell responses to antigen","volume":"126","author":"Xu","year":"2020","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omton.2026.201315_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-0716-0146-4_17","article-title":"Analysis of CAR-Mediated Tonic Signaling","volume":"2086","author":"Calderon","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omton.2026.201315_bib25","article-title":"CAR-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omton.2026.201315_bib26","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.ymthe.2020.07.017","article-title":"Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer","volume":"28","author":"Ko","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201315_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.omton.2026.201315_bib28","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to Address Chimeric Antigen Receptor Tonic Signaling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2026.201315_bib29","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2104758118","article-title":"Dynamic chromatin regulatory landscape of human CAR T cell exhaustion","volume":"118","author":"Gennert","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201315_bib30","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201315_bib31","first-page":"A447","article-title":"394 Combination of a tumor-specific virus and CAR T to specifically and universally target tumors of epithelial origin and overcome challenges of the tumor microenvironment","volume":"13","author":"Liu","year":"2025","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.omton.2026.201315_bib32","article-title":"Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization","volume":"5","author":"Leung","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.omton.2026.201315_bib33","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ymthe.2025.02.026","article-title":"RESET: A TCR-coupled antigen receptor with superior targeting sensitivity and reversible drug-regulated anti-tumor activity","volume":"33","author":"Leleux","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201315_bib34","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201315_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003826","article-title":"Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells","volume":"10","author":"Tokatlian","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201315_bib36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/cyto.a.24893","article-title":"High-throughput screen to identify and optimize NOT gate receptors for cell therapy","volume":"105","author":"Martire","year":"2024","journal-title":"Cytometry. A."},{"key":"10.1016\/j.omton.2026.201315_bib37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.molimm.2020.09.012","article-title":"Engineered T cells directed at tumors with defined allelic loss","volume":"128","author":"Hamburger","year":"2020","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omton.2026.201315_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1493329","article-title":"Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy","volume":"16","author":"DiAndreth","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201315_bib39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chembiol.2005.10.017","article-title":"Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity","volume":"13","author":"Bayle","year":"2006","journal-title":"Chem. Biol."},{"key":"10.1016\/j.omton.2026.201315_bib40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2767-9764.CRC-21-0150","article-title":"Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform","volume":"2","author":"Borrok","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.omton.2026.201315_bib41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12964-021-00811-1","article-title":"Mechanism of MyD88S mediated signal termination","volume":"20","author":"Pustelny","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.omton.2026.201315_bib42","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbrc.2017.11.099","article-title":"The role of N-terminal segment and membrane association in MyD88-mediated signaling","volume":"495","author":"Avbelj","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:40:23Z","timestamp":1790253623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001918"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201315","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An inducible signal 1 booster overcomes limited access to antigen for solid tumor cell therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201315","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201315"}}